Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil

被引:16
|
作者
Diaz, Ricardo Sobhie [1 ]
Hunter, James R. [1 ]
Camargo, Michelle [1 ]
Dias, Danilo [1 ]
Galinskas, Juliana [1 ]
Nassar, Isabela [1 ]
de Lima, Isaac Barbosa [1 ]
Caldeira, Debora Bellini [1 ]
Sucupira, Maria Cecilia [1 ]
Schechter, Mauro [1 ,2 ]
机构
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Fed Univ Rio Janeiro, Rio De Janeiro, Brazil
基金
美国国家卫生研究院;
关键词
Dolutegravir; Resistance associated mutations; Transmitted drug resistance; Virologic failure; Brazil; ANTIRETROVIRAL-NAIVE ADULTS; ONCE-DAILY DOLUTEGRAVIR; INITIAL TREATMENT; DOUBLE-BLIND; SAO-PAULO; SUBTYPE F; HIV-1; RALTEGRAVIR; THERAPY; SURVEILLANCE;
D O I
10.1186/s12879-023-08288-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundSince January 2017, the recommended first-line antiretroviral regimen in Brazil is the fixed-dose combination of tenofovir plus lamivudine with dolutegravir (TL + D). According to the literature, integrase resistance-associated mutations (INRAMs) are rarely found upon virologic failure to first-line dolutegravir plus two nucleoside reverse transcriptase inhibitors. We evaluated the HIV antiretroviral genotypic resistance profile of patients referred for genotyping in the public health system who failed first-line TL + D after at least six months of therapy on or before December 31, 2018.MethodsHIV Sanger sequences of the pol gene were generated from plasma of patients with confirmed virologic failure to first-line TL + D in the Brazilian public health system before December 31, 2018.ResultsOne hundred thirteen individuals were included in the analysis. Major INRAMs were detected in seven patients (6.19%), four with R263K, one with G118R, one with E138A, and one with G140R. Four patients with major INRAMs also had the K70E and M184V mutations in the RT gene. Sixteen (14.2%) additional individuals presented minor INRAMs, and five (4,42%) patients had both major and minor INRAMS. Thirteen (11.5%) patients also presented mutations in the RT gene selected by tenofovir and lamivudine, including four with both the K70E and M184V mutations and four with only M184V. The integrase mutations L101I and T124A, which are in the in vitro pathway for integrase inhibitor resistance, were found in 48 and 19 patients, respectively. Mutations not related to TL + D, thus probable transmitted resistance mutations (TDR), were present in 28 patients (24.8%): 25 (22.1%) to nucleoside reverse transcriptase inhibitors, 19 (16.8%) to non-nucleoside reverse transcriptase inhibitors, and 6 (5.31%) to protease inhibitors.ConclusionsIn marked contrast to previous reports, we report a relatively high frequency of INRAMs among selected patients failing first-line TL + D in the public health system in Brazil. Possible reasons for this discrepancy include delays in detecting virologic failure, patients inadvertently on dolutegravir monotherapy, TDR, and/or infecting subtype.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
    Carles, Joan
    Chirivella, Isabel
    Angel Climent, Miguel
    Gallardo, Enrique
    Gonzalez del Alba, Arancha
    Pablo Maroto, Jose
    Mellado, Begona
    Garcia del Muro, Francisco Xavier
    CANCER AND METASTASIS REVIEWS, 2012, 31 : S3 - S9
  • [22] Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review
    Munoz, Neus
    Sanchez-Delgado, Jordi
    Baylina, Mireia
    Lopez-Gongora, Sheila
    Calvet, Xavier
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (10): : 654 - 662
  • [23] Managing first-line failure
    Cooper, David A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 6 - 6
  • [24] Accumulation of HIV Drug Resistance Mutations in Patients Failing First-Line Antiretroviral Treatment in South Africa
    Sigaloff, Kim C. E.
    Ramatsebe, Tina
    Viana, Raquel
    de Wit, Tobias F. Rinke
    Wallis, Carole L.
    Stevens, Wendy S.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2012, 28 (02) : 171 - 175
  • [25] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Ching-Tso Chen
    Yin-Hsun Feng
    Chia-Jui Yen
    San-Chi Chen
    Yun-Tzu Lin
    Li-Chun Lu
    Chih-Hung Hsu
    Ann-Lii Cheng
    Yu-Yun Shao
    Hepatology International, 2022, 16 : 1199 - 1207
  • [26] Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
    Chen, Ching-Tso
    Feng, Yin-Hsun
    Yen, Chia-Jui
    Chen, San-Chi
    Lin, Yun-Tzu
    Lu, Li-Chun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Shao, Yu-Yun
    HEPATOLOGY INTERNATIONAL, 2022, 16 (05) : 1199 - 1207
  • [27] Switch to dolutegravir in HIV patients responding to a first-line antiretroviral treatment: 48 weeks results
    Tau, Luba
    Ziv-Baran, Tomer
    Cohen-Poradosu, Ronit
    Leshno, Ari
    Alon, Danny
    Shasha, David
    Rapaport, Steven
    Wasserman, Asaf
    Finn, Talya
    Katchman, Eugene
    Hassin, David
    Yust, Israel
    Brofman, Tamar
    Avidor, Boaz
    Turner, Dan
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [28] Procedures after first-line treatment of ovarian cancer
    Thomssen, C
    ONKOLOGIE, 1999, 22 : 27 - 28
  • [29] Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
    Wainberg, Mark A.
    Mesplede, Thibault
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [30] The Absence of Drug Resistance against Dolutegravir in First-Line Therapy is Attributable to Reduced Viral Replicative Fitness
    Wainberg, Mark
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 : 66 - 66